세계 백신 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향 예측(2024-2032년)
Global Vaccine Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
상품코드:1548075
리서치사:Value Market Research
발행일:2024년 07월
페이지 정보:영문 222 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
백신 시장의 세계 수요는 2023년의 1,274억 1,000만 달러에서 2032년에는 1,591억 1,000만 달러 근처 시장 규모에 이를 것으로 추정되며, 조사 기간 2024-2032년의 CAGR은 2.5%로 추정됩니다.
백신은 특정 질병에 대한 면역을 생성하여 사람들을 질병으로부터 보호하는 물질입니다. 백신에는 미생물의 사망이나 약독화한 것이 포함되어 있으며, 이들 미생물은 면역계를 자극하여 항체를 생산합니다. 대부분의 백신은 주사, 비강, 경구로 투여됩니다. 면역계를 활성화 또는 자극하기 위해 이용되는 전략에 의해 백신은 불활화형, 약독형, 톡소이드형, 서브유닛형, 실험형, 가수형, 헤테로형, 결합형 등의 유형으로 분류됩니다. 현재 개발 중이며 아직 상업화되지 않은 백신도 많이 있습니다.
시장 역학
세계 박멸 목표와 인구 증가가 백신 시장 성장을 견인할 것으로 예측됩니다. 매년 200-300만 명의 어린이의 사망과 60만 명의 성인 사망이 예방접종으로 예방됩니다. 그럼에도 불구하고 매년 수백만 명의 생명을 빼앗고 있는 질병이 많아 유효한 백신이 아직 없기 때문에 새로운 개량형 백신의 연구개발이 진행되고 있습니다. 고소득 국가는 세계 백신 매출의 82%를 차지하는 주요 백신 구매 국가입니다. 그러나 백신의 낭비는 시장 수익에 영향을 미치는 큰 문제로 인식되고 있습니다. 또한, 백신을 구입하기 위한 자금이 부족한 국가도 있고, 국가 당국이 충분히 기능하지 않기 때문에 백신 개발에 필요한 자원이나 권한이 없는 국가도 있다는 우려도 있습니다. 이것은 백신의 향후 실행 가능성에 영향을 미칩니다. 성장에 영향을 미치는 이러한 요인을 평가하기 위해 WHO는 예방접종 부족을 측정하고 해결하기 위한 프로그램과 파트너를 지원하는 일련의 도구를 개발하고 다양한 조치를 취하고 있습니다.
이 설문 조사 보고서는 Porter's Five Force 모델, 시장 매력 분석 및 밸류체인 분석을 다룹니다. 이러한 도구는 업계의 구조를 명확하게 파악하고 세계 수준의 경쟁의 매력을 평가하는 데 도움이 됩니다. 또한, 이러한 도구는 백신 세계 시장에서 각 부문을 종합적으로 평가할 수 있습니다. 백신 산업의 성장과 동향은 이 연구에 전반적인 접근법을 설명합니다.
시장 세분화
시장 세분화를 통해 국가별 및 지역별 부문에 대한 자세한 데이터를 제공함으로써 전략 담당자가 각 제품 및 서비스의 대상 계층을 파악하고 향후 비즈니스 기회에 도움을 줄 수 있습니다.
지역 분석
이 섹션에서는 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카에서 백신 시장의 현재 및 미래 수요를 강조하는 지역 전망을 다룹니다. 또한, 저명한 모든 지역에서의 개별 용도 부문 수요·추정·예측에도 초점을 맞추었습니다.
맞춤 요구사항이 있는 경우 당사에 문의하세요. 당사의 설문조사팀은 고객의 요구에 따라 맞춤형 보고서를 제공할 수 있습니다.
The global demand for Vaccine Market is presumed to reach the market size of nearly USD 159.11 Billion by 2032 from USD 127.41 Billion in 2023 with a CAGR of 2.5% under the study period 2024-2032.
Vaccines are the substance that protects people from diseases by producing immunity to a specific disease. It contains a dead or weakened version of microbes; these microbes stimulate immune system to produce antibodies. Most vaccines are given by injection, nasally, or by mouth. Depending on strategies utilised to activate or stimulate immune system,vaccines are classified into different types:inactivated, attenuated, toxoid, subunit, experimental, valence, heterotypic and conjugate. There are number of the vaccines under development and yet to commercialise.
MARKET DYNAMICS
Global eradication goals and population expansion are predicted to drive the growth of the vaccine market. Annually, an estimated 2-3 million child deaths and 600,000 adult deaths are prevented by vaccination. Still, there are many diseases that claim millions of lives yearly and for which effective vaccines are not yet available this is giving rise to research and development of the new and improved vaccine. High-income countries are major purchasers of vaccine constituting 82% of global vaccine sales. However, vaccine wastage is identified as a major problem to affect market revenue. There is also another concern that some countries have insufficient funds to buy vaccine while some countries don't have resource or mandate required to conduct the vaccine development due to poor functioning national authorities. This affects the future viability of the vaccine. To assess these factors affecting growth, WHO is taking various measures by developing a set of tools to support programmes and partners to measure and address under-vaccination.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Vaccine. The growth and trends of Vaccine industry provide a holistic approach to this study.
MARKET SEGMENTATION
This section of the Vaccine market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
This section covers the regional outlook, which accentuates current and future demand for the Vaccine market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Vaccine market include Serum Institute Of India Pvt. Ltd., Seqirus, Sanofi, GSK Plc., Merck & Co. Inc., Pfizer Inc., Moderna Inc., Sinovac, BioNTech SE, AstraZeneca. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
3.7.2 Market Attractiveness Analysis By Route of Administration
3.7.3 Market Attractiveness Analysis By Disease Indication
3.7.4 Market Attractiveness Analysis By Age Group
3.7.5 Market Attractiveness Analysis By Distribution Channel
3.7.6 Market Attractiveness Analysis By Region
4. VALUE CHAIN ANALYSIS
4.1. Value Chain Analysis
4.2. Raw Material Analysis
4.2.1 List of Raw Materials
4.2.2 Raw Material Manufactures List
4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
4.4.1 Direct Marketing
4.4.2 Indirect Marketing
4.4.3 Marketing Channel Development Trend
5. GLOBAL VACCINE MARKET ANALYSIS BY TYPE
5.1. Overview By Type
5.2. Historical and Forecast Data
5.3. Analysis By Type
5.4. Subunit Vaccines (Recombinant vaccines, Conjugate Vaccines, Toxoid vaccines) Historic and Forecast Sales By Regions
5.5. Inactivated Historic and Forecast Sales By Regions
5.6. Live Attenuated Historic and Forecast Sales By Regions
5.7. mRNA vaccines Historic and Forecast Sales By Regions
5.8. Viral vector vaccines Historic and Forecast Sales By Regions
6. GLOBAL VACCINE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.1. Overview By Route of Administration
6.2. Historical and Forecast Data
6.3. Analysis By Route of Administration
6.4. Oral Historic and Forecast Sales By Regions
6.5. Parenteral Historic and Forecast Sales By Regions
6.6. Nasal Historic and Forecast Sales By Regions
7. GLOBAL VACCINE MARKET ANALYSIS BY DISEASE INDICATION
7.1. Overview By Disease Indication
7.2. Historical and Forecast Data
7.3. Analysis By Disease Indication
7.4. Viral Diseases (Hepatitis, Influenza, HPV, MMR, Rotavirus, Herpes Zoster, Covid-19, Others) Historic and Forecast Sales By Regions
7.5. Bacterial Vaccines (Meningococcal Diseases, Pneumococcal Diseases, DPT, Others) Historic and Forecast Sales By Regions
7.6. Cancer Vaccines Historic and Forecast Sales By Regions
7.7. Allergy Vaccines Historic and Forecast Sales By Regions
8. GLOBAL VACCINE MARKET ANALYSIS BY AGE GROUP
8.1. Overview By Age Group
8.2. Historical and Forecast Data
8.3. Analysis By Age Group
8.4. Pediatric Historic and Forecast Sales By Regions
8.5. Adult Historic and Forecast Sales By Regions
9. GLOBAL VACCINE MARKET ANALYSIS BY DISTRIBUTION CHANNEL
9.1. Overview By Distribution Channel
9.2. Historical and Forecast Data
9.3. Analysis By Distribution Channel
9.4. Hospital & Retail Pharmacies Historic and Forecast Sales By Regions
9.5. Government Suppliers Historic and Forecast Sales By Regions
9.6. Others Historic and Forecast Sales By Regions
10. GLOBAL VACCINE MARKET ANALYSIS BY GEOGRAPHY
10.1. Regional Outlook
10.2. Introduction
10.3. North America Sales Analysis
10.3.1 Overview, Historic and Forecast Data Sales Analysis
10.3.2 North America By Segment Sales Analysis
10.3.3 North America By Country Sales Analysis
10.3.4 United States Sales Analysis
10.3.5 Canada Sales Analysis
10.3.6 Mexico Sales Analysis
10.4. Europe Sales Analysis
10.4.1 Overview, Historic and Forecast Data Sales Analysis
10.4.2 Europe By Segment Sales Analysis
10.4.3 Europe By Country Sales Analysis
10.4.4 United Kingdom Sales Analysis
10.4.5 France Sales Analysis
10.4.6 Germany Sales Analysis
10.4.7 Italy Sales Analysis
10.4.8 Russia Sales Analysis
10.4.9 Rest Of Europe Sales Analysis
10.5. Asia Pacific Sales Analysis
10.5.1 Overview, Historic and Forecast Data Sales Analysis
10.5.2 Asia Pacific By Segment Sales Analysis
10.5.3 Asia Pacific By Country Sales Analysis
10.5.4 China Sales Analysis
10.5.5 India Sales Analysis
10.5.6 Japan Sales Analysis
10.5.7 South Korea Sales Analysis
10.5.8 Australia Sales Analysis
10.5.9 South East Asia Sales Analysis
10.5.10 Rest Of Asia Pacific Sales Analysis
10.6. Latin America Sales Analysis
10.6.1 Overview, Historic and Forecast Data Sales Analysis
10.6.2 Latin America By Segment Sales Analysis
10.6.3 Latin America By Country Sales Analysis
10.6.4 Brazil Sales Analysis
10.6.5 Argentina Sales Analysis
10.6.6 Peru Sales Analysis
10.6.7 Chile Sales Analysis
10.6.8 Rest of Latin America Sales Analysis
10.7. Middle East & Africa Sales Analysis
10.7.1 Overview, Historic and Forecast Data Sales Analysis
10.7.2 Middle East & Africa By Segment Sales Analysis
10.7.3 Middle East & Africa By Country Sales Analysis
10.7.4 Saudi Arabia Sales Analysis
10.7.5 UAE Sales Analysis
10.7.6 Israel Sales Analysis
10.7.7 South Africa Sales Analysis
10.7.8 Rest Of Middle East And Africa Sales Analysis
11. COMPETITIVE LANDSCAPE OF THE VACCINE COMPANIES
11.1. Vaccine Market Competition
11.2. Partnership/Collaboration/Agreement
11.3. Merger And Acquisitions
11.4. New Product Launch
11.5. Other Developments
12. COMPANY PROFILES OF VACCINE INDUSTRY
12.1. Top Companies Market Share Analysis
12.2. Market Concentration Rate
12.3. Serum Institute Of India Pvt. Ltd.
12.3.1 Company Overview
12.3.2 Company Revenue
12.3.3 Products
12.3.4 Recent Developments
12.4. Seqirus
12.4.1 Company Overview
12.4.2 Company Revenue
12.4.3 Products
12.4.4 Recent Developments
12.5. Sanofi
12.5.1 Company Overview
12.5.2 Company Revenue
12.5.3 Products
12.5.4 Recent Developments
12.6. GSK Plc.
12.6.1 Company Overview
12.6.2 Company Revenue
12.6.3 Products
12.6.4 Recent Developments
12.7. Merck & Co. Inc.
12.7.1 Company Overview
12.7.2 Company Revenue
12.7.3 Products
12.7.4 Recent Developments
12.8. Pfizer Inc.
12.8.1 Company Overview
12.8.2 Company Revenue
12.8.3 Products
12.8.4 Recent Developments
12.9. Moderna Inc.
12.9.1 Company Overview
12.9.2 Company Revenue
12.9.3 Products
12.9.4 Recent Developments
12.10. Sinovac
12.10.1 Company Overview
12.10.2 Company Revenue
12.10.3 Products
12.10.4 Recent Developments
12.11. BioNTech SE
12.11.1 Company Overview
12.11.2 Company Revenue
12.11.3 Products
12.11.4 Recent Developments
12.12. AstraZeneca
12.12.1 Company Overview
12.12.2 Company Revenue
12.12.3 Products
12.12.4 Recent Developments
Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies
